Western Blotting (WB), ELISA, Immunofluorescence (IF)
Specificity
CLEC2A antibody is human specific. Two alternatively spliced transcript variants have been observed.
Purification
CLEC2A Antibody is affinity chromatography purified via peptide column.
Immunogen
CLEC2A antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human CLEC2A. The immunogen is located within the first 50 amino acids of CLEC2A.
CLEC2A
Reactivity: Human
WB, EIA, IF
Host: Rabbit
Polyclonal
unconjugated
Application Notes
CLEC2A antibody can be used for detection of CLEC2A by Western blot at 1 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
CLEC2A Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
CLEC2A antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
CLEC2A
(C-Type Lectin Domain Family 2, Member A (CLEC2A))
KACL antibody, PILAR antibody, UNQ5792 antibody, CLEC2A antibody, C-type lectin domain family 2 member A antibody, CLEC2A antibody, LOC100847268 antibody, LOC101102719 antibody
Background
CLEC2A Antibody: CLEC2A (C-type lectin domain family 2 member A), also known as PILAR (proliferation-induced lymphocyte-associated receptor) is involved in modulating T-cell expansion. It is a 32 kDa single-pass type II membrane protein that contains one C-type lectin domain in its extracellular region and belongs to the CTL/CTLD superfamily. CLEC2A is mainly expressed in skin and highly expressed in CD8(+), B lymphocytes and naive CD4(+) T cells. Manipulation of CLEC2A signaling may be important for treatment of autoimmune diseases and cancer.